Project Grant K99CA312797
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts Institute of Technology (MIT) a project grant of $133,955 on August 7, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support cancer research training and investigation through July 31, 2027. The grant funds research examining how cancer cachexia—progressive wasting of skeletal muscle, fat, and other tissues observed in pancreatic ductal adenocarcinoma (PDAC) patients—influences...
- Federal Project Grant Award Summary The National Cancer Institute awarded Columbia University's Health Sciences Division a Project Grant of $151,263 under the Cancer Research Manpower program (CFDA 93.398) effective September 1, 2025, with completion targeted for August 31, 2027. This award supports research training and investigator development in cancer research aligned with the National Cancer Program's strategic priorities. The institutional award provides funding to develop research...
- Federal Grant Award Summary Massachusetts General Hospital, operating under The General Hospital Corporation, received a $176,040 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) effective July 1, 2025 through June 30, 2027. This award supports research training and investigation into the relationship between subcellular one-carbon metabolism (OCM), S-adenosylmethionine (SAM) availability, and pancreatic ductal adenocarcinoma...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Massachusetts Medical School $136,840 under the Cancer Research Manpower program (CFDA 93.398) on December 1, 2025, for a project extending through May 11, 2028. This project grant funds research investigating replication gap suppression mechanisms in chemoresistant BRCA1 and BRCA2 (BRCA) mutant hereditary breast and ovarian cancers (HBOC). The research aims to identify critical factors contributing...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital (MGH) a Project Grant totaling $188,080 under the Cancer Research Manpower program (CFDA 93.398) on August 22, 2025, with a completion date of August 21, 2027. This award supports a mixed-methods research study titled "Enhancing Access in Pancreatic Cancer: Examining Facilitators and Barriers to Tertiary Referral for Complex Oncologic Surgical Care," which addresses the...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $123,823 to the University of Maryland, Baltimore under the Cancer Research Manpower program (CFDA 93.398) for the period June 1, 2026 through May 31, 2028. This award supports research and training activities focused on characterizing transcriptomic, genomic, and microenvironmental heterogeneity in pancreatic precancerous lesions, specifically intraductal papillary mucinous neoplasms (IPMNs) and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Dana-Farber Cancer Institute, Inc. a Project Grant of $159,304 under the Cancer Research Manpower program (CFDA 93.398) for the period July 1, 2025 through June 30, 2027. This award supports research training and investigator development focused on identifying signaling pathways that govern tumoricidal macrophage function in pancreatic cancer. The project aims to elucidate receptor-ligand interactions that enable...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $141,195 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to The University of Texas MD Anderson Cancer Center for research titled "Deciphering the Role of Tumor Suppressor Gene Deficiencies in Modulating PDAC Response to Oncogenic KRAS Inhibition and Immunotherapy." The award was obligated on May 15, 2026, with a completion date of April 30, 2028. This funding supports a K99/R00 Pathway...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $275,990 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective September 2, 2025, through August 31, 2026. This award supports research and development of engineered living materials (ELMs) as programmable therapeutic implants for pancreatic ductal adenocarcinoma (PDAC), a cancer with a five-year survival rate below 5%. The project builds...
- Federal Project Grant Award Summary The University of Vermont & State Agricultural College received a $129,624 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective July 14, 2025, through June 30, 2027. This award supports research investigating adipose tissue (AT) as a novel facilitator of tumor growth and cancer cachexia (CC) in lung cancer patients. The funded research develops and utilizes an improved...
The University of Massachusetts Medical School received a $142,251 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective June 1, 2026, through May 31, 2028. This award supports research training and career development activities focused on investigating bidirectional tumor-host crosstalk in cachexia and pancreatic ductal adenocarcinoma (PDAC). The research addresses the significant clinical problem of cancer-associated cachexia, a paraneoplastic syndrome affecting approximately 80% of PDAC patients, through a K99/R00 Pathway to Independence Award mechanism designed to support the transition of early-stage investigators to independent faculty positions. Under this funding, the investigator will conduct two primary research aims examining the molecular drivers of cachexia onset, with particular focus on the role of parathyroid hormone-related peptide (PTHrP) in pancreatitis-associated cachexia and the investigation of novel mediators contributing to cachectic wasting in the context of obesity and PDAC. The project utilizes mouse models to characterize functional mechanisms and explore the adipose tissue-tumor cell interactions that dysregulate cancer-associated signaling pathways. This research directly supports the National Cancer Program's strategic priorities in cancer research workforce development and advancement of scientific knowledge regarding cancer-associated complications.Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $142.3k | 5/13/26 |